



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/075,490
				Filing Date	February 12, 2002
				First Named Inventor	Julie A. Johnson
				Art Unit	3737
				Examiner Name	Unassigned
Sheet	1	of	2	Attorney Docket Number	UF-265CXC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

RECEIVED
MAY 14 2002
AC 3700 MAIL ROOM

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 01/06910 A3	02-01-2001	U of Cincinnati	All	
	F2	WO 01/79252 A1	10-25-2001	Genaissance Pharmaceuticals, Inc.	All	
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					


Examiner Signature		Date Considered	8/14/02
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/075,490
Filing Date	February 12, 2002
First Named Inventor	Julie A. Johnson
Group Art Unit	3737
Examiner Name	Unassigned
Attorney Docket Number	UF-265CXC1

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	R1	Bengtsson, Kristina <i>et al.</i> , "Polymorphism in the β_1 -Adrenergic Receptor Gene and Hypertension", <i>Circulation</i> (2001) 104:187-190; Pub: American Heart Association, Inc.	
	R2	Büscher, R. <i>et al.</i> , "In-Vivo Studies do not Support a Major Functional Role for the Gly389Arg β_1 -adrenoceptor Polymorphism in Humans," <i>Pharmacogenetics</i> (2001) 11(3):199-205; Pub: Lippincott Williams & Wilkins	
	R3	Dishy, Victor <i>et al.</i> , "The Effect of Common Polymorphisms of the β_2 -Adrenergic Receptor on Agonist-Mediated Vascular Desensitization", <i>The New England Journal of Medicine</i> (2001) 345(14):1030-1035; Pub: Massachusetts Medical Society	
	R4	Dishy, V. <i>et al.</i> , "ARG389HLY Beta-1 Adrenoceptor Polymorphism Does Not Affect Agonist-Mediated Responses <i>in Vivo</i> ", <i>Clin. Pharmacology & Therapeutics</i> (2001) 69(2):P5 at PI-17; Pub: American Society for Clinical Pharmacology and Therapeutics	
	R5	Green, Stuart A. <i>et al.</i> , "The Ile164 β_2 -adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G_s ", <i>European Journal of Pharmacology</i> (2001) 421:141-147; Pub: Elsevier Science B.V.	
	R6	Humna, Larisa M. <i>et al.</i> , "Effects of Beta ₁ -Adrenoceptor Genetic Polymorphisms on Resting Hemodynamics in Patients Undergoing Diagnostic Testing for Ischemia", <i>The American Journal of Cardiology</i> (2001) 88:1034-1037; Pub: Excerpta Medica, Inc.	
	R7	Jia, Haiyan <i>et al.</i> , "Association of the G_{α_s} Gene with Essential Hypertension and Response to β -Blockade," <i>Hypertension</i> (1999) 34(1):8-14; Pub: American Heart Association, Inc.	
	R8	Jia, Haiyan <i>et al.</i> , " β_2 -Adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians", <i>Journal of Hypertension</i> (2000) 18(6): 687-693; Pub: Lippincott Williams & Wilkins	
	R9	Johnson, Julie A. <i>et al.</i> , "Metoprolol Minimizes Nighttime Blood Pressure Dip in Hypertensive Black Males, <i>Am. J. Hypertens.</i> (1995) 8(3):254-259; Pub: American Journal of Hypertension, Ltd.	
	R10	Moore, J.D., <i>et al.</i> , "Racial Differences in the Frequencies of Cardiac $\beta(1)$ -Adrenergic Receptor Polymorphisms: Analysis of c145A>G and c1165G>C," <i>Hum Mutat</i> (1999) 14(3):271 [Mutat. & Polymorph. Report #65] Pub: Online	
	R11	Schäfers, Rafael F. <i>et al.</i> , "Haemodynamic characterization of young normotensive men carrying the 825T-allele of the G-protein β_3 subunit", <i>Pharmacogenetics</i> (2001) 11:461-470; Pub: Lippincott Williams & Wilkins	
	R12	Siffert, W., <i>et al.</i> , "Worldwide Ethnic Distribution of the G Protein β_3 Subunit 825T Allele and its Association with Obesity in Caucasian, Chinese, and Black African Individuals," <i>J Am. Soc. Nephrol.</i> (1999) 10(9):1927-30; Pub: American Society of Nephrology	
	R13	Waltman, Claire, <i>et al.</i> , "Polymorphism of the Gene Encoding the Alpha Subunit of the Stimulatory G-Protein of Adenylyl Cyclase (GNAS1)" <i>Hum Genet</i> (1994) 93(4):477-8; Pub: Springer-Verlag	
	R14	Xie, H.G. <i>et al.</i> , "Beta-1 and Beta-2 Adrenergic Receptor (BAR) Polymorphisms and Obesity in African-Americans (AA) and Caucasian-Americans (CA)", <i>Clin. Pharmacol. & Ther.</i> (Feb. 2001) P74 at PIII-40; Pub: American Society for Clinical Pharmacology and Therapeutics	
	R15	Xie, H.G. <i>et al.</i> , "Interethnic Differences in β_2 Adrenoceptor Polymorphisms in African-American, Caucasian, and Chinese Populations" (abstract), <i>Clin. Pharmacol. & Ther.</i> (Feb. 1999) 65(2):133 at PI-65; Pub: Mosby, Inc.	


Examiner
SignatureDate
Considered

8/14/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



COPY OF PAPERS
ORIGINALLY FILED

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/075,490
Filing Date	February 12, 2002
First Named Inventor	Julie A. Johnson
Group Art Unit	3737
Examiner Name	Unassigned
Attorney Docket Number	UF-265CXC1

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	Taylor, D.R., et al., "The Influence of Polymorphism at Position 16 of the β_2 -Adrenoceptor on the Development of Tolerance to β -agonist," <i>Journal of Asthma</i> , 2000, pp. 691-700, vol. 37 no. 8, Marcel Dekker, Inc.	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		
	R14		
	R15		
	R16		

Examiner
Signature

Date
Considered

8/14/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.